GPCR in the 13F filings
Structure Therapeutics Inc · CUSIP 86366E106
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 14 Nov 2023
- latest of these filings; the earliest 13 Nov 2023
- Managers listing it
- 7
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 2 listed it in both
- Shares listed
- 6,248,525
- combined, among listed positions
- Reported value
- $307m
- combined, at the quarter end
Managers listing GPCR in Q3 2023
7 of 7 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| T. Rowe Price Associates Inc | 2,513,563 | $127m | under 0.1% | Added | n.a. | 14 Nov 2023 (the filing on sec.gov) |
| Janus Henderson Group Ltd | 2,091,323 | $97m | 0.06% | Added | n.a. | 14 Nov 2023 (the filing on sec.gov) |
| Point72 Asset Management LP | 747,100 | $38m | 0.11% | Added | +316,100 | 14 Nov 2023 (the filing on sec.gov) |
| Capital Research Global Investors | 344,848 | $17m | under 0.1% | New | new | 13 Nov 2023 (the filing on sec.gov) |
| Holocene Advisors LP | 281,291 | $14m | 0.06% | New | new | 14 Nov 2023 (the filing on sec.gov) |
| Woodline Partners LP | 170,000 | $8.6m | 0.10% | Held | 0 | 14 Nov 2023 (the filing on sec.gov) |
| Capital World Investors | 100,400 | $5.0m | under 0.1% | New | new | 13 Nov 2023 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsnew position · 344,848 shares now+344,848
- Point72 Asset Management LPexisting position · 747,100 shares now+316,100
- Holocene Advisors LPnew position · 281,291 shares now+281,291
- Capital World Investorsnew position · 100,400 shares now+100,400
Reductions
No reduction among listed positions.
New positions and exits
New (3)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2023 | 1 | $4.0m | n.a. | n.a. |
| Q2 2023 | 2 | $25m | n.a. | n.a. |
| Q3 2023 | 7 | $307m | n.a. | n.a. |
| Q4 2023 | 5 | $314m | 4 | 1 |
| Q1 2024 | 5 | $439m | 4 | 0 |
| Q2 2024 | 8 | $603m | 7 | 1 |
| Q3 2024 | 5 | $738m | 4 | 1 |
| Q4 2024 | 4 | $429m | 4 | 0 |
| Q1 2025 | 3 | $258m | 2 | 1 |
| Q2 2025 | 3 | $244m | 2 | 2 |
| Q3 2025 | 2 | $284m | 0 | 2 |
| Q4 2025 | 7 | $1.5bn | 16 | 10 |
| Q1 2026 | 5 | $636m | 16 | 10 |
| Q2 2026 | 3 | $686m | 9 | 14 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GPCR and LLY →GPCR and JNJ →GPCR and VRTX →Choose a stock to compare with GPCR →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GPCR, latest filings →Back to the 13F Explorer →